Where does Arca Biopharma, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Arca Biopharma, Inc. ranks #34,302 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Arca Biopharma, Inc. hold?

Arca Biopharma, Inc. holds 7 US utility patents granted between 2015 and 2023, spanning 10 technology areas.

What is Arca Biopharma, Inc.'s Innovation Score?

Arca Biopharma, Inc. has an Innovation Score of 40.8 out of 100 (top 35% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Arca Biopharma, Inc. focus on?

Arca Biopharma, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 7 patents, ranking #2,588 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Arca Biopharma, Inc.'s patent grant rate increasing or decreasing?

Arca Biopharma, Inc.'s recent grant velocity is -25% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Arca Biopharma, Inc.'s patents?

Arca Biopharma, Inc.'s patents average 15.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Arca Biopharma, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Arca Biopharma, Inc.

USPTO PatentsView assignee record - 7 granted patents across 10 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Arca ranks #34,302 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 10 technology areas.

#34,302
of 49,997 US assignees by volume: Top 35%
by Innovation Score (40.8/100): 15.1
avg claims per patent: -25%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R34302 · US Corporation #34,302 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #34,302/49,997
PHOTO-FINISH Aquarius Spectrum
CPC-FOCUS A61P · 10 areas
INNOV-PAR 40.8/100
CLAIMS-RICH 15.1 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -25% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aquarius Spectrum Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Arca’s 40.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (18%) Velocity 13.3 pts (33%) Breadth 11.2 pts (27%) Claim depth 9.1 pts (22%)

Qualcomm Incorporated · highest

85
Arca Biopharma · this assignee

41
3D Lighting… · lowest

7

What this shows Arca's Innovation Score is 40.8/100 (top 35% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Arca?

Each dot is one of Arca’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Arca’s own 15.1 claims/patent is at or below the 18.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Arca vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Arca's grants concentrate

Arca Biopharma, Inc. is a focused PatentsView assignee: 10 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2016. By volume, Arca sits between Aquarius Spectrum Ltd. and Argo-hytos Group AG.

Arca's three-year grant acceleration

Arca Biopharma, Inc. shows 2 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Aquarius Spectrum

7
Aquimo

7
Aquis Wasser-luft…

7
ARC Technology Ho…

7
Arcadis Corporate…

7
Ardent Sound

7
ARE Telecom Incor…

7
Argo-hytos Group

7
Arca Biopharma ◀

7

What this shows Arca holds 7 patents at rank #34,181, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Arca

By rank, the assignees closest to #34,181 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Arca's primary technology class.

Arca's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 35% higher than 65% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Arca Biopharma, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	28.6%
2016	1	14.3%
2017	1	14.3%
2021	1	14.3%
2022	1	14.3%
2023	1	14.3%

Which technologies does Arca Biopharma, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

A61B - DIAGNOSIS; SURGERY; Identification 6

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 4

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 4

C07D - Heterocyclic Compounds 4

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

C07K - Peptides 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Arca Biopharma, Inc.'s patent record in context - here's where to go next.

Arca Biopharma, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #34,302 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Arca Biopharma, Inc. against Aquarius Spectrum Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.